Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard Thomas Penson, M.B.,B.S.

Co-Author

This page shows the publications co-authored by Richard Penson and Neil Horowitz.
Connection Strength

1.263
  1. Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
    View in: PubMed
    Score: 0.173
  2. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33.
    View in: PubMed
    Score: 0.130
  3. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
    View in: PubMed
    Score: 0.117
  4. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
    Score: 0.116
  5. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
    View in: PubMed
    Score: 0.110
  6. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
    View in: PubMed
    Score: 0.109
  7. Penson RT, Kornblith AB, Lee J, Roche M, Atkinson T, Gibson CD, Horowitz NS, Krag KJ, Krasner CN, Matulonis UA. Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590.
    View in: PubMed
    Score: 0.106
  8. Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
    View in: PubMed
    Score: 0.106
  9. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
    View in: PubMed
    Score: 0.092
  10. Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 Oct; 159(1):72-78.
    View in: PubMed
    Score: 0.062
  11. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Oct 10.
    View in: PubMed
    Score: 0.058
  12. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
    View in: PubMed
    Score: 0.035
  13. Duda DG, Cohen KS, Ancukiewicz M, di Tomaso E, Zhu AX, Penson RT, Horowitz NS, Batchelor TT, Willett CG, Jain RK. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544.
    View in: PubMed
    Score: 0.026
  14. Roche M, Matulonis U, Krasner C, Penson R, Horowitz N, Berkenblit A, Findley M, Lee J, Horick N, Seiden MV. Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.